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ABSTRACT 26 
Background: Cryptococcal meningitis has high mortality. Flucytosine is a key treatment but is expensive 27 
and rarely available. The anti-cancer agent tamoxifen has synergistic anti-cryptococcal activity with 28 
amphotericin in vitro. It is off-patent, cheap, and widely available. We performed a trial to determine its 29 
therapeutic potential. 30 
Methods: Open label randomized controlled trial. Participants received standard  care - amphotericin 31 
combined with fluconazole for the first two weeks - or standard care plus tamoxifen 300mg/day. The 32 
primary end point was Early Fungicidal Activity (EFA) - the rate of yeast clearance from cerebrospinal fluid 33 
(CSF). Trial registration https://clinicaltrials.gov/ct2/show/NCT03112031. 34 
Results: 50 patients were enrolled, (median age 34 years, 35 male). Tamoxifen had no effect on EFA (-35 
0.48log10 colony-forming units/mL/CSF control arm versus -0.49 tamoxifen arm, difference -36 
0.005log10CFU/ml/day, 95%CI: -0.16, 0.15, P=0.95). Tamoxifen caused QTc prolongation. 37 
Conclusion: High dose tamoxifen does not increase the clearance rate of Cryptococcus from CSF. Novel, 38 
affordable therapies are needed. 39 
Funding: The trial was funded through the Wellcome Trust Asia Programme Vietnam Core Grant 106680 40 
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Cryptococcal meningitis is a leading cause of death in HIV-infected patients, with an estimated 223,000 46 
cases in 20141. The vast majority of infections are due to C. neoformans, and occur in low-income tropical 47 
settings. Current international guidelines recommend initial induction treatment with amphotericin 48 
combined with flucytosine, followed by consolidation therapy with fluconazole2. This combination 49 
delivers the fastest rates of clearance of yeast from cerebrospinal fluid (CSF) and the best survival rates3,4. 50 
However, even on this gold standard therapy, 30% of patients will die within 10 weeks of diagnosis3,4. 51 
Adjunctive therapy with corticosteroids, which has proven beneficial in other forms of meningitis, results 52 
in worse outcomes5.  53 
Cryptococcal meningitis can also occur in HIV-uninfected patients, including immunocompetent 54 
people and those with other causes of immunosuppression. Survival rates are similar to those seen in 55 
HIV-infected patients. There are few data from randomized controlled trials to guide treatment in these 56 
circumstances. In Vietnam around 20% of cases of cryptococcal meningitis are in HIV-uninfected 57 
patients6.  Disease is predominantly due to the C. neoformans VNIa-5 lineage; C. gattii is responsible for 58 
around 25% of cases6-9.  59 
There has been little progress in development of antifungal drugs for cryptococcal meningitis. 60 
Amphotericin and flucytosine are each more than 60 years old; the last novel drug class developed was 61 
the azoles, introduced 30 years ago. Access to flucytosine is severely restricted by availability and cost, 62 
meaning it is rarely used where disease burden is highest. Despite being off-patent, it has been subject to 63 
extraordinary price rises in recent years, with a 2 week course now costs around 30,000 USD in the USA10. 64 
Flucytosine is an unattractive prospect for generic manufacturers, because the location of the majority of 65 
patients and the few indications outside cryptococcal disease promise only limited financial returns. 66 




driven interest in drug re-purposing11-13. Re-purposing can be a solution for neglected diseases provided 68 
the new indication accounts for only a minority of total prescriptions, and the de facto indications are 69 
sufficiently prevalent to ensure availability, price stability and affordability.  70 
Tamoxifen, a selective estrogen receptor modulator used to treat breast cancer, has anti-cryptococcal 71 
activity, appearing to act synergistically when combined with other antifungals against the type strain in 72 
vitro, and to be fungicidal when combined with fluconazole in the mouse infection model11,12. We found it 73 
to act synergistically with amphotericin against two-thirds of clinical isolates of Cryptococcus neoformans 74 
and C. gattii from our archive and to have an additive interaction when combined with fluconazole in 75 
vitro14.  76 
Tamoxifen is concentrated in brain tissue (10 to 100-fold compared with plasma) and macrophage 77 
phagosomes (a site of growth for Cryptococcus spp.), is off-patent, cheap (~10US cents/tablet) and widely 78 
available15,16. Therefore, it is a promising candidate for the treatment of cryptococcal meningitis. 79 
Pharmacokinetic data suggest that doses 5 to 10-fold that used in breast cancer (typically 30mg/day) 80 
should deliver plasma concentrations of tamoxifen greater than the Minimum Inhibitory Concentration 81 
90 (MIC90 16ug/mL) of Vietnamese clinical isolates15. Such doses have been used, and well-tolerated, in 82 
small cell lung cancer, desmoid tumours, and prostate cancer. These illnesses have comparable or better 83 
1 year survival rates than cryptococcal meningitis17. While generally well-tolerated, acute side effects that 84 
could be detrimental from short-course treatment include QT prolongation of the cardiac 85 
de/repolarisation cycle, although the risk of life-threatening arrhythmias appears to be low18.  86 
In Vietnam induction treatment for cryptococcal meningitis consists of  amphotericin combined with 87 
fluconazole, consistent with WHO recommendations where flucytosine is unavailable2. However, this 88 
combination is less effective than amphotericin with flucytosine, resulting in slower rates of fungal 89 




survival is generally robust; improving the potency of antifungal therapy is likely to be an effective way to 91 
reduce deaths3-5. The rate of clearance of yeast from CSF associated with an antifungal treatment (the 92 
early fungicidal activity, EFA) is a sensitive measure able to detect differences between treatment 93 
regimens likely to be associated with survival benefits with far fewer patients than studies powered to 94 
survival itself19. Small studies powered to this endpoint can serve to filter treatment regimens that can be 95 
taken forward in larger trials19,20. We performed an open-label randomised controlled trial to determine 96 
whether combining tamoxifen with amphotericin B and fluconazole results in enhanced EFA in  HIV 97 
infected and uninfected patients with cryptococcal meningitis, and to generate safety data as a prelude to 98 
a larger trial powered to mortality 17. 99 
 100 
Methods 101 
Study design and participants 102 
The study design is described in detail in the published protocol17. In brief, we enrolled 50 patients in 103 
two hospitals in Ho Chi Minh City – the Hospital for Tropical Diseases and Cho Ray Hospital. Eligible adult 104 
patients (≥18 years of age) had a clinical syndrome consistent with cryptococcal meningitis and one or 105 
more of: (1) positive cerebrospinal fluid (CSF) India ink; (2) C. neoformans cultured from CSF or blood; (3) 106 
positive cryptococcal antigen Lateral Flow Antigen Test (LFA) in CSF. All patients were tested for HIV 107 
infection in accordance with standard of care. We excluded patients who were pregnant, had a history of 108 
thromboembolic disease, had received more than 4 days of anti-cryptococcal antifungal therapy, had any 109 
other indication for tamoxifen, had renal failure, or a rate-corrected (Framingham formula) QT interval 110 





Patients were randomized to receive either standard of care induction antifungal therapy or standard 113 
of care plus tamoxifen. Standard of care antifungal therapy consisted of intravenous amphotericin B 114 
deoxycholate 1mg/kg/day (Amphotret, Bharat Serums and Vaccines, India) combined with oral 115 
fluconazole 800mg/day (Zolmed, Glomed Pharmaceuticals, Vietnam) for the first 14 days following 116 
randomisation. Tamoxifen (Nolvadex, AstraZeneca UK Ltd) 300mg/day was given orally. Amphotericin 117 
was infused over 4 hours after prehydration with normal saline and potassium supplementation21. 118 
Fluconazole and tamoxifen were administered simultaneously. All medication was directly observed while 119 
the patient was in hospital; all participants were in-patients for at  least the first 14 days of the study.  120 
Following induction therapy all patients received fluconazole 800mg once daily for 8 weeks. HIV-121 
infected patients received daily pneumocystis prophylaxis with trimethoprim– sulfamethoxazole. 122 
Antiretroviral therapy was instituted 5-6 weeks after diagnosis via the national treatment programme. 123 
Randomisation 124 
Randomization was in a ratio of 1:1, in blocks of 4 or 6, stratified by HIV serostatus (rapid test) and 125 
treating centre. The computer generated randomization list was password protected and stored on a 126 
secure server to which only the study pharmacist had access. Enrolment logs specific to each centre were 127 
used to assign patients to the next available sequential number and corresponding sealed treatment 128 
pack. 129 
Outcome Measures 130 
The primary outcome was Early Fungicidal Activity (EFA), defined as the rate of decline in culturable 131 




Secondary outcomes included survival until 10 weeks after randomization, disability at 10 weeks, 133 
frequency of grade 3, 4 or serious adverse events, immune reconstitution inflammatory syndrome (IRIS), 134 
QTc prolongation, visual deficit at 10 weeks, and time to new neurological events. Adverse events were 135 
defined according to the Common Terminology Criteria for Adverse Events (CTCAE) and categorized 136 
according to the Medical Dictionary for Regulary Activities system organ class. We categorized prolonged 137 
QTc intervals using this classification as normal (<450ms for males, <460ms for females), mildly prolonged 138 
(grade 1 or 2, ≥450ms for males or ≥460 for females but ≤500ms) and grade 3 or 4 (>500ms). Disability at 139 
10 weeks was categorised as good, intermediate, poor, or death, as described previously3,5.  140 
Monitoring and laboratory investigations 141 
Lumbar puncture was performed on study entry, days 3, 7 and 14 following randomization, and more 142 
frequently if indicated. Fungal burden was determined as previously described3. Twelve-lead 143 
electrocardiograms were recorded twice daily (10 seconds at 50mm/sec), immediately before and 2 144 
hours after administration of tamoxifen during the first 14 days, and on days 21 and 28. The QT interval 145 
was manually determined by measuring the interval in 3 limb and 3 chest leads, to calculate the median. 146 
The median QT interval was corrected (QTc) for rate using the Framingham formula[20]. Calmodulin 147 
inhibitors such as tamoxifen have previously been suggested to inhibit CD4 cell apoptosis in HIV infected 148 
patients22. CD4 counts were measured at baseline and at study week 10. The full laboratory investigation 149 
schedule is detailed in the published protocol17. Outpatient assessments with medication review were 150 
performed weekly until 4 weeks and at the completion of 6 and 10 weeks; more frequent review 151 
occurred if clinically indicated. Adherence following hospital discharge was assessed using pill counts. 152 
Cryptococcus isolates were typed using URA5-RFLP and underwent (microbroth) antifungal susceptibility 153 




Sample size 155 
Sample size considerations were based on two separate simulation experiments using data from our 156 
previously published trials in cryptococcal meningitis3,5. The estimated power was based upon 10,000 157 
repetitions of each experiment. The full methodology is available within the published protocol17. Based 158 
on these simulations, enrolling 25 subjects per treatment group provided 80% and 90% power to detect a 159 
difference in EFA of -0.11 or -0.13 log10 colony-forming units/ml/day, respectively. This size of effect has 160 
previously been associated with survival benefit3,5.  161 
Statistical analysis 162 
For the primary outcome, all recorded longitudinal quantitative fungal count measurements up to day 163 
17 following randomization (allowing for some delays in the day 14 sampling) were included in the 164 
analysis. EFA, defined as the decline in fungal count (slope), was modeled based on a joint model 165 
consisting of a  survival model and a linear mixed effects model with longitudinal log10 CSF quantitative 166 
culture fungal counts as the outcome. In the linear mixed effect model, we modeled the treatment 167 
groups and the time since enrolment and their interaction as fixed covariates. We used random patient-168 
specific intercepts and slopes. The model was implemented in a Bayesian framework using Rstan. It 169 
allows appropriate handling of detection limits with longitudinal measurements and also allows 170 
adjustment for informative dropout due to early death within the first 17 days following 171 
randomization25,26. 172 
For the secondary outcomes, overall survival was visualized using Kaplan-Meier curves for each treatment 173 
arm and the comparison between them was based on the Kaplan Meier estimates of 10 week mortality. 174 
The percentage of individuals with disabilities at 10 weeks and with adverse events of grade 3 or 4 were 175 




exact test was used27. We presented the median (IQR) of the difference in CD4 counts over 10 weeks and 177 
compared their distributions using the Mann-Whitney-Wilcoxon rank sum test. We compared the trend in 178 
QTc over the period of study drug administration (i.e. the first 14 days) between the two treatment arms 179 
using a linear mixed effect model which allowed for different non-linear trends between the pre-dose and 180 
post-dose measurements. We then used the output of the fitted linear mixed effect model to compute 181 
the differences in QTc between treatment arms by study day, separately for pre-dose and 2 hours post-182 
dose measurements. Further details of the analytical approach are available in the the Supplementary 183 
Appendix in the Statistical Analysis Plan. 184 
Ethics and study oversight 185 
The study protocol was approved by the Ethical Review Committees of the Hospital for Tropical 186 
Diseases, Cho Ray Hospital, and the Vietnamese Ministry of Health, and by the Oxford University Tropical 187 
Research Ethics Committee. A trial steering committee with 2 independent members oversaw the 188 
running of the trial, and an independent data and safety monitoring committee oversaw trial safety. The 189 
first safety analysis was performed after the first 20 patients had reached the primary endpoint. The 190 
funding bodies and drug manufacturers played no role in the study design, implementation, analysis, or 191 
manuscript preparation. All the authors made the decision to submit the manuscript for publication and 192 
vouch for the accuracy and completeness of the data and analyses presented. The trial was registered at 193 
https://clinicaltrials.gov/ct2/show/NCT03112031.  194 
 Results 195 
Trial recruitment 196 
The study recruited between October 2017 and May 2018. We screened 70 patients, enrolling 50 (40 197 




arm. Reasons for exclusion are shown in the study flow diagram (see Figure 1). One patient who was 199 
assigned to the intervention arm did not receive tamoxifen because of severe transaminitis.  200 
 201 
Baseline characteristics 202 
The baseline characteristics of the patients were broadly balanced between treatment groups. There 203 
were slightly more patients with normal Glasgow coma scores in the control group than in the 204 
intervention group (24 of 26 versus 19 of 24, see Table 1). 205 
Primary outcome 206 
There was no detectable difference in the early fungicidal activity (EFA) of the two treatment regimens 207 
(see Figure 2A). In the intention-to-treat analysis, the rates of fungal decline per day were -0.48 and -0.49 208 
log10 colony-forming units (CFU)/ml/day in the control and tamoxifen groups respectively  (difference -209 
0.005 log10 CFU/ml/day, 95%CI: -0.16, 0.15); p-value = 0.95, see Table 2). There was no detectable 210 
difference in EFA in the per-protocol population analysis, or by HIV infection status (see Table 2). 211 
 212 
Secondary endpoints 213 
The secondary outcomes in terms of mortality, disabilities, and change in CD4 count are summarized 214 
in Table 3.  Death occured in 8 of 24 patients in the tamoxifen group and 7 of 26  in the control group 215 
(Kaplan-Meier mortality estimates 34% and 27% respectively, risk difference 6.5%; 95% confidence 216 
interval [CI], -19.2% to 32.1%; P=0.62 Figure 2B). Fewer patients in the tamoxifen arm were classified as 217 




difference in change in CD4 counts in HIV patients by study arm over the 10 week period of follow-up (see 219 
Table 3). 220 
The number of patients having  grade 3 or 4 adverse events were similar between treatment arms (see 221 
Table 4), with the exception of QTc prolongation events. Eight patients had  grade 3 or 4 QTc prolongation 222 
events in the tamoxifen arm, compared with one  in the control arm (p=0.02). The trend and difference in 223 
QTc intervals over the first 2 weeks of treatment are shown in Figure 3Error! Reference source not 224 
found.. Tamoxifen resulted in  QTc prolongation over the two week treatment period (p<0.001).  225 
Three patients in the tamoxifen arm had grade 3 or 4 ventricular extra-systole events compared with 226 
none in the control arm (p=0.21). A 33 year old male patient who had received tamoxifen suffered a 227 
cardiorespiratory arrest following a convulsion on day 21 of the study. He had no history of pre-existing 228 
cardiac disease. His ECG on admission had been normal with a QTc of 409 ms, and when performed 229 
routinely on the morning of day 21 showed mild sinus bradycardia (57 beats/minute) and a QTc interval 230 
of 477ms. The arrest was not associated with ventricular arrhythmia although he had had grade 3 231 
prolongation of QTc during the first 14 days of the study, which had resolved following tamoxifen 232 
interruption. 233 
Microbiology and susceptiblity testing 234 
 235 
All HIV infected patients, and 7 HIV uninfected patients, had meningitis due to Cryptococcus neoformans 236 
molecular group VNI. Three HIV uninfected patients had disease due to Cryptococcus gattii (VGI). All  237 
isolates underwent susceptibility testing. The MIC90 of amphotericin B and fluconazole were 2mg/L and 238 
4mg/L respectively. The MIC90 of tamoxifen was 8mg/L. We estimated the presence of drug interactions 239 
by calculating the fractional inhibitory concentration index (FICI) for each isolate. This was ≤0.5 240 
(suggestive of a possible synergistic interaction) for tamoxifen combined with amphotericin in 6 isolates 241 





We wanted to determine whether tamoxifen could be repurposed as an affordable treatment for 244 
cryptococcal meningitis. Our study was powered to detect an increase in the rate of yeast clearance of at 245 
least -0.11 log10 CFU/ml/day when tamoxifen was added to standard of care therapy. Differences of this 246 
order of magnitude are associated with improved survival in patients in low income settings 3-5. Despite 247 
having previously shown that tamoxifen had activity in vitro against historical clinical isolates of C. 248 
neoformans, we found its addition had no impact on EFA. Therefore we do not believe that proceeding to 249 
a larger trial, powered to survival, is justified. 250 
It is not clear why tamoxifen did not provide benefit in our patients. The  susceptibilities of the 251 
Cryptococcus isolates from this study to tamoxifen, fluconazole and amphotericin, were similar to those 252 
of isolates from our previous clinical trials 14,28. However, in contrast with our previous findings we found 253 
evidence of synergy when tamoxifen was combined with amphotericin in only 12% (95CI 5%, 24%) of 254 
isolates from the trial. This compares with the rate in archived isolates of 67% (95CI  47%, 81%)14.  255 
Synergy has been suggested as an explanation for the superiority of the amphotericin-flucytosine 256 
combination which has delivered improved yeast clearance and survival in a number of trials29. In this 257 
study, we lack sufficient numbers of isolates where tamoxifen-amphotericin synergy is seen to be able to 258 
determine whether synergy per se influences EFA. 259 
A second potential explanation is that we may have failed to attain sufficient concentrations of 260 
tamoxifen in our patients. We chose a dose of 300mg/day, based upon the MIC90 of tamoxifen against 261 
our historical isolates (16 mg/L) and the expected plasma concentrations this would achieve. Given that 262 
tamoxifen is concentrated in the brain (10 to 100-fold), and in macrophage phagosomes, we consider it 263 
unlikely that we did not reach drug concentrations greater than the MIC90 at the disease site, although it 264 




The rates of adverse events in our study were similar between patients receiving tamoxifen and those 266 
in the control arm. Our study was powered to detect a difference in the rate of clearance of yeast from 267 
CSF and therefore may have lacked power to detect differences in rates of rarer adverse events. 268 
However, there was greater prolongation of the QTc interval in patients on tamoxifen. The mechanism 269 
through which tamoxifen causes QT interval prolongation in humans is unknown. In animals there is 270 
evidence that the block is multi-channel, due to both inhibition of the IKR and ICa channels
30-32. Such multi-271 
channel block is considered to confer a reduced risk of life-threatening arrhythmias compared with drugs 272 
that block single ion channels. While we did not have any cases of ventricular tachycardia in our study, 273 
there was an episode of cardiac arrest in the tamoxifen arm. There are multiple potential causes of 274 
cardiac arrest in patients with cryptococcal meningitis, including intracranial pathology and electrolyte 275 
disturbances. The cardiac arrest in our study occurred on day 21, one week after administration of 276 
tamoxifen had finished. However, given tamoxifen’s half-life of 5 to 7 days, and the doses used, it is 277 
possible that this event was related.  Fluconazole is also a recognised cause of QT prolongation. Here, the 278 
mechanism is believed to be through modulation of the Ikr current of the cardiac depolarisation cycle
33. 279 
However, we found little evidence of significant QT prolongation in patients in the control arm of our 280 
study, and in fact the acute effect of administration of fluconazole was shortening of the QTc interval.  281 
Our experience with tamoxifen is similar to that reported with the anti-depressant drug sertraline. 282 
Sertraline has in vitro fungicidal activity against Cryptococcus neoformans and a synergistic effect when 283 
combined with fluconazole. Results from a pilot dose-finding study of adjunctive sertraline for 284 
cryptococcal meningitis suggested it was a safe and potentially effective treatment, although no 285 
contemporaneous controls were enrolled in the trial34. Subsequently a large randomised controlled trial 286 
powered to mortality was stopped due to futility having enrolled 460 patients35. There was no difference 287 
in survival or EFA between the standard therapy or sertraline boosted treatment arms. Of note, a small 288 




difference in EFA  when sertraline was added to amphotericin and fluconazole, although only 12 patients 290 
were enrolled and formal statistical testing was not performed36. However, it lends further support for 291 
the screening of antifungal treatments in small scale studies using this endpoint.  292 
Other drugs suggested as repurposing candidates for cryptococcal meningitis include the calcium 293 
antagonists, such as nifedipine and its sister drugs, used to treat hypertension, and flubendazole, an 294 
antihelminthic37. Flubendazole is perhaps the most promising of these, appearing to be more potent in 295 
vitro than fluconazole, and active against Cryptococcus isolates across a range of fluconazole 296 
susceptibilities. It crosses the blood brain barrier in mice, but data are lacking regarding humans38. While 297 
nifedipine crosses the blood brain barrier, it seems unlikley that normal doses and oral administration 298 
would reach the plasma levels needed to inhibit Cryptococcus growth. However, given our experiences 299 
with tamoxifen, and those of others with sertraline, we would caution that better laboratory screening 300 
methods than those currently in use are needed to identify potential new treatments for cryptococcal 301 
meningitis. 302 
In the mean time, improving access to flucytosine remains a key goal. Progress has been made through 303 
efforst to increase generic manufacture through the the Unitaid- Clinton Health Access Initiative  for 304 
Advanced HIV Disease Initiative’s partnership with the Global Fund and the President's Emergency Plan 305 
for AIDS Relief. This has resulted in price reductions allowing 2 week treatment courses to be procured 306 
for around $100 in some locations.  307 
Conclusion 308 
Despite apparent in vitro anti-cryptococcal effect including synergy when combined with 309 
amphotericin,  tamoxifen does not increase the rate of clearance of yeast from cerebrospinal fluid in HIV 310 
infected and uninfected patients with cryptococcal meningitis; it is unlikely to result in clinical benefit. 311 




repurposable drugs in clinical endpoint studies. However, the failure of both tamoxifen and sertraline in 313 
recent studies underlines the importance of developing novel, specifically anti-cryptococcal drugs. This 314 
will require the support of government and charitable bodies to ensure treatments remain affordable. 315 
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Table 1. Clinical and investigation characteristics of patients at study entry  
 
Characteristic Total Tamoxifen  Total Control  
 N N (%) or IQR¥ N N (%) or IQR¥ 
Male sex  24 17 (71) 26 18 (69) 
Median age in years  24 35  
(31, 39) 
26 32  
(25, 35) 
History of intravenous drug use  24 3 (13) 26 3/26 (12) 
HIV infection 24 19 (83) 26 21/26 (81) 
Current antiretroviral-therapy use  
None 24 18 (75) 26 22 (84) 
≤3 months duration 24 4 (17) 26 2 (8) 
>3 months duration 24 2 (8) 26 2 (8) 
Median duration of illness — days 24 14  
(10, 25) 
26 12  
(7, 28) 
Symptoms      
Headache 24 24 (100) 26 26 (100) 
Fever 24 22 (92) 26 23 (88) 
Neck stiffness 22 20 (91) 26 21 (81) 
Seizures 24 2 (8) 26 3 (12) 
Abnormal visual acuity 22 6 (27) 26 4 (15) 
Papilledema 21 2 (10) 25 1 (4) 
Glasgow Coma Scale score 24  26  
15  19 (79)  24 (92) 
11–14  5 (21)  2 (8) 
<11  0 (0)  0 (0) 
Cranial nerve palsy  
None 24 19 (79) 26 23 (88) 
Cranial nerve VI 24 4 (17) 26 1 (4) 
Other cranial nerve 24 1 (4) 26 3 (11) 
Investigations 




Median CSF white-cell count in HIV infected 
patients — cells/mm3 
18 38.5  
(7, 52) 
20 27  
(10, 55) 
Median CSF white-cell count in HIV uninfected 
patients — cells/mm3 
5 122  
(64, 187) 
5 94  
(45, 117) 
Median CSF glucose — mmol/liter 24 2.47  
(1.70, 3.14) 





Median blood glucose — mmol/liter 24 5.86  
(4.92, 6.84) 
26 6.21  
(5.11, 7.81)  
Median CSF: blood glucose ratio  24 0.40  
(0.24, 0.53) 
25 0.37  
(0.16, 0.45) 
Median CSF fungal count — log10 CFU/ml 24 4.60  
(3.90, 5.17) 
26 5.16  
(3.17, 5.87)  
Median CD4 count in HIV infected patients — 
cells/mm3      
17 20  
(8, 49) 
21 17  
(9, 45) 
Median CD4 count in HIV uninfected patients — 
cells/mm3 
5 376  
(348, 382) 
5 504  
(305, 968) 
Median creatinine — mg/dl 24 0.82  
(0.66, 1.05) 
26 0.78  
(0.66, 0.98) 




¥ Median, interquartile range (IQR) for continuous data and N (%) for categorical data 
 336 






Table 2.  Primary outcome: Early Fungicidal Activity over the first 2 weeks following randomization (log10 colony 
forming units (CFU)/ml/day). 
 Treatment Arm  





 N Change/day (95% CI⸙) N Change/day (95% CI⸙) (95% CI⸙)  
Intention-to-treat  24 -0.49  
(-0.62, -0.37) 





Per-protocol  23 -0.48  
(-0.61, -0.36) 







19 -0.49  
(-0.65, -0.37) 







5 -0.42  
(-0.74, -0.21) 







⸙ 95% CI corresponds to Bayesian 95% credible intervals 342 
ⱡp-value refers to crude “Wald-type” tests of the mean estimate divided by its standard deviation of the 343 
















Table 3. Secondary outcomes: Death, Disability and Change in CD4 count 





Risk difference  
% (95%CI) 
p- valueⱡ 
Intention-to-treat population 8/24 (34) 7/26 (27) 6.47 
(-19.15, 32.09) 
0.62 
Per-protocol population 7/23 (31) 6/25 (24) 6.50 
(-18.90, 31.89) 
0.62 
HIV infected patients 7/19 (37) 6/21 (29) 8.39 
(-20.99, 37.77) 
0.58 
HIV uninfected patients 1/5 (20) 1/5 (20) 0.00 
(-49.58, 49.58) 
1.00 
Disability at 10 weeks  0.14 
Good 2/23 (9) 9/25 (36)   
Intermediate  7/23 (30) 6/25 (24)   
Severe disability 6/23 (26) 3/25 (12)   
Death 8/23 (35) 7/25 (28)   
Disability at 10 weeks in HIV 
infected patients  
 0.05 
Good 2/18 (11) 8/20 (40)   
Intermediate 5/18 (28) 6/20 (30)   
Severe disability 4/18 (22) 0/20 (0)   
Death 7/18 (39) 6/20 (30)   
Disability at 10 weeks in HIV 
uninfected patients  
 
 0.68 
Good 0/5 (0) 1/5 (20)   
Intermediate 2/5(40) 0/5 (0)   
Severe disability 2/5 (40) 3/5 (60)   
Death 1/5 (20) 1/5 (20)   









































Table 4. Grade 3 or 4 Adverse Events by 10 weeks  
Event Tamoxifen (N=24) Control (N= 26) p-valueⱡ 
Number of patients with Grade 3 or 4 adverse events (%)  
Any adverse event 24 (100) 26 (100) 1.0 
New neurological events 9 (38) 7 (27) 0.62 
New AIDS-defining illness (HIV patients only)  3 (16) 5 (24) 0.58 
New cardiac events 9 (38) 4 (15) 0.145 
Supraventricular tachycardia 1 (4) 0 (0) 0.48 
Ventricular extrasystoles 3 (13) 0 (0) 0.21 
Right Bundle Branch Block  0 (0) 1 (4) 1.00 
QTc prolongation 8 (33) 1 (4) 0.02 
Myocardial infarction 0 (0) 1 (4) 1.00 
Cardiac arrest 1 (4) 0 (0) 0.48 
Other cardiac adverse events 1 (4) 1 (4) 1.0 
Laboratory abnormalities  
Anemia 18 (75) 18 (69) 0.89 
Leukopenia 2 (8) 2 (8) 1.0 
Thrombocytopenia 2 (8) 4 (15) 0.74 
Elevated aminotransferase 2 (8) 4 (15) 0.74 
Raised Creatinine 
 
3 (13) 6 (23) 0.55 
Hyperkalemia 2 (8) 6 (23) 0.48 
Hypokalemia 17 (71) 20 (77) 0.87 
Hyponatremia 18 (75) 23 (88) 0.39 
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Figure 1. Trial flow chart: Enrollment, Randomization and Follow-up 369 
  370 
26 patients were included in 
the intention-to-treat analysis 
25 were included in per 
protocol analysis 
- 1 received only 4 days 
of amphotericin B  
24 patients were included in        
the intention-to-treat analysis 
23 were included in per protocol 
analysis 
- 1 patient did not receive 
tamoxifen due to 
transaminitis 
 
70 patients were assessed for eligibility 
50 patients underwent randomisation 
24 patients were assigned to the 
tamoxifen arm 
26 patients were assigned to 
the control arm 
20 were excluded:  
 2 had known cardiac 
conduction defects 
 1 was pregnant 
 15 declined to participate 
 1 had QTc baseline > 500 ms 






Figure 2.  371 
A. Decline in fungal count in CSF as measured in colony-forming units (CFU) per milliliter over the first 2 
weeks of treatment by treatment arm. Data from individual patients are shown in grey lines. Bold blue 
lines show estimated mean with 95% credible intervals (shaded band) of CSF fungal counts based on the 
joint model described in the statistical analysis. The rate of decline was -0.49 log10CFU/ml/day in 
patients receiving tamoxifen versus -0.48 log10CFU/ml/day in control patients. The horizontal dashed 
lines represent the value of detection limit (4.5 CFU/ml). The fitted line crosses the horizontal dashed 
lines of the detection limit value after day 8 because 25% and 75% of patients had fungal counts under 
the detection limit at day 8 and 15, respectively.  
 




in the control arm versus 8 in the tamoxifen intervention arm by 10 weeks (estimated risk 27% versus 34%, 















Figure 3. Change in QTc interval over the first 2 weeks of treatment by study arm. Faint lines display 382 
change in individual patient QTcs; bold lines display the estimated mean and and shaded bands the 95% 383 
Confidence Intervals; blue = control arm, red = tamoxifen arm. The maximum median difference in the 384 
QTc intervals between study arms immediately prior to drug administration was 37.07ms (95% CI: 21.09, 385 
53.04) and occurred on day 9 of the study. The largest difference in median QTc 2 hours post-drug 386 
administration was 33.44ms (95% CI: 18.67, 48.21) and occurred on day 8 of the study. Additional details 387 
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Section 1 Statistical Analysis Plan  18 
Purpose 19 
This document details the planned analyses and endpoint derivations for the randomized open label 20 
trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis 21 
(NCT03112031) as outlined in the study protocol. It focuses on the analysis for the main clinical 22 
trial outcomes and does not include analysis for any subsidiary studies.  23 
Statistical software  24 
Data derivations will be performed with the statistical software SAS v9.4 (SAS Institute, Cary, North 25 
Carolina, US). All statistical analyses will be performed with the statistical software R version R 26 
version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria)[1]. 27 
Interim analyses and early stopping of the trial 28 
Interim analyses for this trial will be conducted by an independent data and safety monitoring board 29 
with statistical expertise (Chair: Tim Peto) after the first 20 cases have reached the primary 30 
endpoint (completed the first 2 weeks of treatment following randomization or died), as 31 
detailed in the study protocol. 32 
Raw data will be transferred from the study statistician (Nhat Le Thanh Hoang) to the Data Safety and 33 
Monitoring Board (DSMB) chair and statistician (Tim Peto) in csv format (csv data can be viewed 34 
in Excel and imported to any statistical software) together with R code to generate all summary 35 
tables.  36 
The trial is not blinded with placebo; however, the clinician investigators of the trial will not be informed 37 
of the interim analyses results, but only the decision as to whether to continue the trial or not, 38 
and whether any additional safety reporting is needed.  39 
Based on this information, the DSMB chair and statistician will generate the output tables and distribute 40 
the interim report amongst the Data Monitoring and Ethics Committee (DMEC) members. 41 
 3 
Analysis populations 42 
Intention-to treat population (ITT) 43 
The primary analysis population for all analysis is the full analysis population containing all randomized 44 
patients except for those mistakenly randomized without cryptococcal meningitis. Patients not 45 
receiving any study treatment will still be included in the ITT. Patients will be analyzed according 46 
to their randomized arm (intention-to-treat).  47 
Per-protocol population 48 
The primary endpoint will also be analyzed on the per-protocol population, which will exclude the 49 
following patients: major protocol violations and those receiving less than 1 week of 50 
administration of the randomized study drug for reasons other than death. 51 
Derivation rules for the definition of study populations 52 
The following will be considered as “major protocol violations”:  53 
- Pregnancy 54 
- Less than 1 week of amphotericin B antifungal therapy after randomization for reasons other 55 
than death (interpreted in the same way as for the study drug, see below).  Amphotericin B 56 
antifungal therapy is recorded on the antifungal drug (AFDR) form. 57 
- Less than 1 week of administration of tamoxifen study drug for reasons other than death: To 58 
allow that study drug is stopped up to 3 days prior to death, this will be interpreted as receiving 59 
<7 days of study drug for those who did not die within the first 9 days and as receiving less than 60 
[day of death]-3 doses of study drug for those who died earlier (i.e. <6 doses for patients who 61 
die on day 9, <5 doses for patients who die on day 8, …, no study drug at all for patients who die 62 
on days 1-4) . 63 
Baseline characteristics  64 
 4 
Baseline characteristics will be summarized as median (interquartile-range (IQR)) for continuous data 65 
and n (%) for categorical data. The amount of missing data for each baseline characteristic will 66 
also be displayed. 67 
Formal comparisons of baseline characteristics between study arms are discouraged by most 68 
statisticians (see e.g. Senn SS (2008): Statistical Issues in Drug Development, 2nd Edition, Wiley 69 
[p. 98f]) but mandated by some journals. To satisfy all potential publishers, we will calculate p-70 
values (based on the Wilcoxon rank sum test for continuous and Fisher’s exact test categorical 71 
data) but will only report them if mandated by the journal. 72 
Baseline/date of randomization is defined as the date of the first dose of study treatment 73 
(AMPHOTERICINBDATESTART where DAY=1 in dataset AFDR). If a subject did not receive any 74 
study treatment at all, baseline will be defined as the date of the baseline (history and 75 
examination) assessment (BASE.ASSDTC).  76 
The following baseline characteristics will be summarized by treatment arm [with derivation rules in 77 
brackets]: 78 
BASE: Baseline – History and Examination 79 
All recorded variables in the BASE form with the following modifications: 80 
- Free text specifications will not be summarized. 81 
- If dates are given (e.g. date of birth, prior HIV diagnosis, or prior to cryptococcal meningitis), the 82 
time from that date to baseline will be summarized rather than the date. 83 
- For fluconazole prophylaxis: only yes/no, not the duration will be summarized 84 
- For any antifungal treatment for THIS CURRENT diagnosis of cryptococcal meningitis BEFORE 85 
randomization: Only the given antifungals (yes/no), whether it was fluconazole monotherapy 86 
(yes/no) and the maximum recorded days on any prior antifungal treatment will be reported.  87 
 5 
- Other Opportunistic Infection Prophylaxis up to this admission: Only the given drugs (co-88 
trimoxazole, isoniazid, and/or other) will be summarized. 89 
- Glasgow coma score (GCS) will also be summarized as a categorical variable with values ≤10, 11-90 
14, and 15. 91 
- For visual acuity, the worst result of both eyes will also be summarized. 92 
- Cranial nerve palsies (CNP) will be summarized as “CNP 6” [CNPLeft6 or CNPRight6 ticked], 93 
“Other CNP” [at least one CNP other than CNP 6 ticked], “None” [CNPnone ticked] or “Unable to 94 
assess” [CNPUnableAssess ticked]. 95 
HEMA (Laboratory investigations – Hematology), CHEMIS (Laboratory investigations – Biochemistry), 96 
MICRO (Microbiology) and HIVFU (CD4 and CD8 count) 97 
 98 
Baseline results for all values (with proper unit conversion) will be recorded. If no values are available 99 
before or at enrolment, values up to one day post enrolment will be used as baseline values for 100 
hematology, chemistry, and values up to 14 days post enrolment will be imputed as baseline 101 
values for CD4 and CD8. (The latest CD4 value recorded on the Base form will also be included in 102 
this derivation as long as it did not occur >3 months (91 days) prior to enrolment.)  For 103 
chemistry, blood glucose values recorded on the lumbar puncture form will also be included in 104 
the derivation. 105 
For microbiology tests, the baseline test result will be summarized as “positive” if at least one positive 106 
test result was recorded up to 3 days post enrolment, and “negative” if at least one negative 107 
and no positive test result was recorded. 108 
LP (Lumbar puncture)  109 
Baseline results for the following values (with proper unit conversion, if necessary) will be recorded: 110 
Opening and closing pressure, WCC, % of lymph, % of neut, % of mono, % of eosin, protein, csf 111 
 6 
glucose, csf/blood glucose ratio), and yeast quantitative count. If no values are available at or 112 
before enrolment, values up to 1day post enrolment will be used as baseline values. For the 113 
calculation of the csf/blood glucose ratio, missing blood glucose values on the lumbar puncture 114 
form will be imputed with the blood glucose value recorded on the chemistry form if that value 115 
is from the same day as the csf glucose value.  116 
Test results for microbiology cerebrospinal fluid (CSF) tests, the baseline test result will be summarized 117 
as “positive” if at least one positive test result was recorded up to 3 days post enrolment, and 118 
“negative” if at least one negative and no positive test result was recorded. 119 
IMAGING (XRAY and BRAINSCAN) 120 
The number of patients with a chest Xray, a brain magnetic resonance imaging (MRI), or a brain 121 
computerized tomography (CT) scan at baseline (allowing -7/+2 days) and the respective 122 
numbers of abnormal findings for each imaging method will be summarized. 123 
Electrocardiogram (ECG) findings 124 
Baseline ECG findings will be presented according to treatment group in terms of heart rate, corrected 125 
QT interval (median, IQR, proportion > 500ms). The QT corrected (QTc) will be classified as 126 
“normal” (<450ms for males, <460ms for females), mildly prolonged (≥450ms for males or ≥460 127 
for females but ≤500ms) and prolonged (>500ms). 128 
Baseline QTc category values will be summarized by treatment arm. Frequency of omitting doses during 129 
treatment if QTc remains >500ms will be also summarized by treatment arm.  130 
Planned analyses 131 
Baseline table for all variables as detailed above for the ITT population will be presented by treatment 132 
group. 133 
Primary endpoint – Rate of CSF sterilization during the first 2 weeks 134 
 7 
All recorded longitudinal quantitative fungal count measurements up to day 17 (allowing for some 135 
delays in the day 14 measurements) will be included in the analysis. Early Fungicidal Activity 136 
(EFA) defined as fungal decline (slope) will be modeled based on a linear mixed effects model 137 
with longitudinal log10-CSF quantitative culture fungal counts as the outcome, the treatment 138 
groups and the time since enrolment, with their interaction, as fixed covariates and random 139 
patient-specific intercepts and slopes. The lowest measurable quantitative count is 5 colony-140 
forming units (CFU)/ml and values below the detection limit (which correspond to recorded 141 
values of 0) will be treated as <4.5 CFU/ml, i.e. non-detectable measurements will be treated as 142 
left-censored longitudinal observations. If a patient who misses day 1 measurement completely 143 
at random, we will exclude this patient from the analysis; otherwise we keep this patient in the 144 
analysis. Based on this model, EFA will be compared between the two treatment arms in all 145 
patients (ITT), in the PP population, and subgroups defined by HIV status (uninfected; infected) 146 
and baseline fungal burden (<5 log10 CFU/ml; ≥ 5 log10 CFU/ml). For the ITT population, the 147 
comparison between two arms will also be adjusted for study site and HIV status. Correction for 148 
multiple testing (Hochberg procedure as implemented in R function multtest:: mt.rawp2adjp) of 149 
all the p-values from the tests for difference effects on EFA between two treatment arms or 150 
interaction tests between treatment and subgroups will be provided.  151 
The model will be implemented with the R package Rstan version 2.19.2 which allows to appropriately 152 
handle detection limits for longitudinal measurements and also to adjust for the selection bias 153 
due to early death in the first 14 days. Stan code will be provided in the appendix. Reported 154 
“95% confidence intervals” correspond to Bayesian 95% credible intervals and the reported “p-155 
values” refer to crude “Wald-type” tests of the mean estimate divided by its standard deviation. 156 
In case Monte Carlo Markov chain diagnostics plots of the fitted stan models indicate failure of 157 
 8 
the algorithm we will report results from a mixed model with a detection limit (but ignoring 158 
truncation by death) instead and this will be implemented with the R package lmec version 1.0.  159 
Secondary Endpoints-Survival until 10 weeks after randomization 160 
Derivation of overall survival until 10 weeks after randomization 161 
- Definition of time to death: [date of death or censoring] - [date of randomization] + 1 162 
- Definition event indicator: = 1 if patient died = 0 otherwise 163 
- [Date of randomization]: date of the baseline which is derived in Baseline characteristic section 164 
- [Date of death]:  165 
- Final status is death (FINAL.FINALSTT =2) and the corresponding date of death is 166 
FINAL.DEATHDATE2. 167 
- [Date of censoring]:  168 
 If a final status form is available for the patient (which should be the case for every 169 
patient at completion of the study) then the date of censoring is defined as the date 170 
of study completion (FINAL.FINALDATE1) or, if the patient did not complete the 171 
study, the date of last contact (FINAL.LASTDATE3). 172 
 If the patient is still under follow-up, i.e. no final status form is available, the date of 173 
censoring is defined as the last recorded date of an inpatient or outpatient 174 
assessment, the week 10, a GCS, hematology, or blood chemistry date, or a study 175 
drug administration date. 176 
Planned analysis 177 
- Overall survival will be visualized using Kaplan-Meier curves by treatment arm and displayed 178 
with separated panel for each HIV status. The analysis will be based on a Cox proportional 179 
hazards regression model with HIV status as stratum variable and treatment arm is the only 180 
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covariate. We will test for proportional hazards of the treatment effect by means of Schoenfeld 181 
residuals (as implemented in R function survival::cox.zph).  182 
- If we have enough event (at least 30 events in total), survival will be modeled with a 183 
multivariable Cox regression model including the following covariates in addition to the 184 
treatment group: baseline log10-fungal load (modeled linearly), Glasgow coma score less than 185 
15 (yes or no), interaction between HIV infection status and treatment, and Anti Retrovirus 186 
(ARV) treatment status at study entry (naïve or experienced).    187 
Subgroup analyses: The following subgroups are pre-defined 188 
- Per protocol analysis – yes 189 
- HIV serostatus (infected, uninfected) 190 
- Quantitative fungal count at enrolment (<10^5 cells/ml, ≥10^5 cells/ml CSF) 191 
Potential heterogeneity of the treatment effect across sub-groups will be tested using likelihood ratio 192 
tests for an interaction term between treatment and the grouping variable. All the p-values from 193 
these interaction tests and the test of the treatment effect in survival of the ITT population will 194 
be corrected for multiple testing (Hochberg procedure as implemented in R function multtest:: 195 
mt.rawp2adjp) due to the small sample size of the first interim analysis n=20, we won’t perform 196 
subgroup analysis and only do it in the final analysis.  197 
Secondary Endpoints-Disability at 10 weeks 198 
Derivation: The disability score assessed at week 10 is composed of two sub-scores: 199 
- The “two simple questions” score [ACTHELP and ISPROBLEM in datasets WEEK10]:   200 
 If answer to the first question= yes; outcome is classified as ‘severe disability’  201 
 If answer to the second question = yes; outcome is classified as ‘intermediate’  202 
 If answer to both questions = no; outcome is classified as ‘good’  203 
- The modified Rankin score: [LB30 in datasets WEEK10] 204 
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 If Rankin score=1; outcome will be classified as ‘good’ 205 
 If Rankin score =2 or=3; outcome will be classified as ‘intermediate’ 206 
 If Rankin score =4, =5 or=6; outcome will be classified as ‘severe disability’ 207 
[Note that the Rankin scale is coded as taking values from 1-6 on the database, i.e. +1 compared to the 208 
levels 0-5 according to the published study protocol.] 209 
The worst disability outcome from either questionnaire (“two simple questions” or Rankin score) will be 210 
used for analysis. Disability will be defined as “death” if the patient died before the scheduled 211 
time point.  212 
Planned analysis 213 
The ordinal 10-week score (“good”> “intermediate”> “severe”> “death”) will be compared between the 214 
two arms with a proportional odds logistic regression model depending on the treatment arm 215 
and HIV infection status. The result will be summarized as a cumulative odds ratio with 216 
corresponding 95% confidence interval and p‐value. Patients lost to follow up will be analyzed 217 
according to their last recorded disability status. If the fraction of patients lost to follow-up 218 
exceeds 10%, we will also perform an alternative analysis based on multiple imputation of 219 
missing values. See section Treatment of missing values (multiple imputation). 220 
Secondary endpoint – Clinical adverse events and new laboratory adverse abnormalities 221 
 222 
Derivation: Adverse events (AE) are all events recorded on the NEW CARDIAC ADVERSE EVENT (NCAE), 223 
NEW NEUROLOGICAL EVENT (NNE), NEW AIDS DEFINING ILLNESS (NADI), or OTHER ADVERSE 224 
EVENT (OAE) forms. All grade 3&4 AE are collected and will be considered as serious adverse 225 
events (SAE); grade 1&2 AE are only collected for NCAE, NNE, and NADI events but not OAE. 226 
New laboratory abnormalities are defined as any worsening of a lab value to grade 3 or 4 (including 227 
changes from grade 3 to 4) compared to the subject's previous lab value. In addition, to be 228 
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conservative, if a subject's baseline lab missing value, the worst post-enrolment lab value will be 229 
considered a new lab abnormality if it is of grade 3 or 4. A grading table for laboratory 230 
abnormalities is provided in the Appendix. 231 
Planned analysis  232 
- Summary of all reported AE – overall (separate summaries by type only and by type and subtype 233 
will be produced) 234 
- Summary of all grade 3&4 AE – overall and by HIV status 235 
- Summary of grade 3&4 AE with onset within the first 2 weeks by type 236 
- Summary of grade 3&4 AE with onset during weeks 3-4 by type 237 
- Summary of grade 3&4 AE with onset during weeks 5-10 by type 238 
- Summary of total number of grade 3&4 AE per patient 239 
- Summary of new laboratory abnormalities  240 
All the summaries will report the frequency of specific adverse events both in terms of the total number 241 
of events as well as the number of patients with at least one event.  The proportion of patients 242 
with at least one such event (overall and for each specific event separately) will be presented 243 
and (informally) compared between the two treatment groups based on Fisher’s exact test.    244 
Secondary endpoint - QT prolongation 245 
The QTc will be classified as “normal” (<450ms for males, <460ms for females), mildly prolonged 246 
(≥450ms for males or ≥460 for females but ≤500ms) and prolonged (>500ms). All recorded QTc 247 
intervals in the first 14 days of treatment and day 21, day 28 following randomization will be 248 
included in the analysis. All the measurement after 14 days will be considered as pre-dose 249 
measurement and all the QTc measurement values at the time of omitting dose during 250 
treatment will be considered as missing values. The main summary measure is the number of 251 
patients who has prolonged QTc within the first 14 days and the number of events of QTC 252 
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prolongation per patient within the first 14 days per arm. The test for the different effect of 253 
treatment arm on QTC prolongation will be based on a linear mixed effect model to the QTc 254 
data in which will allow for different trends over the pre-dose and post-dose measurements. 255 
The linear mixed effect model was implemented with the R package “lmec”. In details, we model 256 
the relation between time and QTc in a flexible way using restricted cubic splines. We include an 257 
interaction term between the treatment arm and both time variables. A random patient-specific 258 
intercept and slope is included to account for the heterogeneity of individuals. The model can be 259 
written as follows:  260 
Yi(t, posti, treatmenti)
= α + ai + (ns(t, df = 3) + ns(t, df = 3) ∗ treatmenti) ∗ I(posti = 0)
+ (ns(t, df = 3) + ns(t, df = 3) ∗ treatmenti) ∗ I(posti == 1) + bi ∗ t + ϵ(t),  
where,  261 
- Yi(t, posti, treatmenti): QTc measurement at day t (t = 0, … ,14, ), of the pre and 2 hours post-262 
dose measurement in treatment group treatmenti of patient i, 263 
- ns(t, df = 3): natural spline function of time with 3 degree of freedom, 264 
- post = 0 if for pre-dose measurement and =1 for post-dose measurement, 265 
- treatment =0 for control arm and =1 for Tamoxifen arm, 266 
- ai and bi are random intercept and random slope of the mixed model,     267 
- ϵ(t) is the measurement error. 268 
Based on this model, longitudinal of QTc measurements will be compared between treatment arms over 269 
the first 14 days of treatment following randomization. In addition, we then used the output of 270 
the fitted linear mixed effect model to compute the differences in QTc between treatment arm 271 
by study day, separately for pre-dose and 2 hours post-dose measurements, based on the delta 272 
method[2]. 273 
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Analysis of other secondary outcomes 274 
Secondary endpoint – Rate of Immune reconstitution inflammatory syndrome (IRIS) until 10 weeks 275 
Derivation: The derived endpoint will be the competing risks endpoint of the time to first IRIS or death 276 
defined as: 277 
Time to event = [date of first IRIS event or death or censoring] - [date of randomization] + 1 278 
Event type:  279 
- 0: “censored”: if patient is censored (no IRIS events or death recorded) 280 
1: “IRIS”: if patient had an IRIS event (any adverse event recorded as IRIS) 281 
2: “prior death”: if patient died without prior IRIS 282 
Planned analysis 283 
The rate of IRIS will be modeled with cause-specific proportional hazards models with treatment as the 284 
only covariate and stratification by HIV infection status, taking into account the competing risk 285 
of prior death. Non-parametric estimates of the cumulative incidence functions for the two 286 
competing events (IRIS/relapse and prior death) will also be calculated and displayed by 287 
treatment arm and tested using Gray log-rank test for sub-distribution hazard.  288 
Secondary endpoint – Rate of Cryptococcal Meningitis Relapse in the 10 weeks after randomization 289 
As for the endpoint “Rate of IRIS until 10 weeks” (see above) will be analyzed.  290 
Secondary endpoint – Visual deficit at 10 weeks. 291 
The visual acuity at 10 weeks is recorded on a 6-point scale and will be summarized by treatment arm 292 
for each eye separately, and overall where “overall” is defined as the worst recorded acuity of 293 
either eye. The odds of having “normal acuity” (amongst all surviving patients with a visual 294 
assessment) will be informally compared between the treatment arms with a logistic regression 295 
model adjusted for HIV status. 296 
Secondary endpoint – Time to new neurologic event or death until 10 weeks 297 
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Derivation: The derived endpoint will be the competing risks endpoint of the time to first new 298 
neurological event or death defined as: 299 
Time to event = [date of first neurological event or death or censoring] - [date of randomization] + 1 300 
Event type:   301 
- 0/ “censored”: if patient is censored (no neurological event or death recorded) 302 
1/ “NNE”: if patient had a new neurological event (defined below)  303 
2/ “prior death”: if patient died without a prior new neurological event  304 
Neurological events are defined as any grade 3 or 4 new neurological events or any fall in GCS ≥2 points, 305 
for ≥ 48hrs (which will also be programmed separately based on recorded longitudinal GCS).  306 
Planned analysis: The time to the first new neurological event or death until 10 weeks will be analyzed in 307 
the same way as overall survival. 308 
Secondary endpoint – Longitudinal measurements of intracranial pressure during the first 2 weeks 309 
This endpoint will be modeled using a mixed effect model as described for the primary outcome 310 
Secondary endpoint – the change of CD4 cell counts over 10 weeks of survived patients 311 
The change of CD4 cell counts over 10 weeks of survived patients will be summarized and compared 312 
using the Kruskal-Wallis rank sum test, separately for HIV status.   313 
Other exploratory analyses 314 
Will be performed as appropriate. 315 
Treatment of missing values (multiple imputation) 316 
Multiple imputation will be performed if do this is the amount of missing values is large. Multiple 317 
imputation by chained equations as implemented in the R package “mice” will be used to deal 318 
with missing covariate values for all the Cox regression analysis and the proportional odds 319 
logistic regression analysis for disability at 10 weeks. Specifically, 20 imputed sets will be 320 
generated and the dataset for multiple imputation will include the following variables: 321 
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- Baseline variables: continent, country, age, sex, GCS, on ARV at study entry (no/ yes but ≤ 3 322 
months/ yes, > 3 MONTHS), CD4 cell count 323 
- CSF measurements: opening pressure and yeast quant counts at baseline [both log-transformed] 324 
- Outcomes: overall survival until 10 weeks after randomization, Rankin score at 10 weeks (using 325 
method polr in mice package). 326 
- Time-to-event outcomes (i.e. overall survival) will be included as the cumulative (cause-specific) 327 
baseline hazard at the observed event or censoring time and an event indicator as 328 
recommended by White and Royston (Statist. Med. 2009; 28:1982–1998). 329 
Additional planned auxiliary analyses 330 
Summary of time to ARV initiation:  331 
- Categorized outcome: On ARVs at study entry/ARVs started after study entry/No ARVs 332 
documented. 333 
- Median (IQR) time to ARV initiation in those who started ARV after study entry. 334 
- Details for subjects with no ARVs documented: Subject died within <42 days without ARV/ 335 
subject died after >=42 days without ARV/ subject alive but no ARVs documented. 336 
Number of chest X-rays, CT scans and MRI performed after baseline and proportion with an abnormal 337 
result. 338 
Summary whether study drug was terminated before 2 weeks (for reasons other than death) by 339 
treatment group – based on tick-box on final status form. Summary of the number of days of 340 
tamoxifen treatment after enrolment   341 
Appendix 342 
Grading of laboratory abnormalities  343 
 344 
Laboratory tests Grade 3 Grade 4 
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Hematology 
Hemoglobin 6.5 –7.9g/dl <6.5 g/dl 
White cell count 1.0 - 1.9 K/l or g/L <1.0 K/l or g/L 
Neutrophils NEU % xWBC=NEU K/l :0.5 – 1.0 K/l NEU % xWBC=NEU K/l <0.5 K/l 
Platelets 25 – 50 K/l or g/L <25 K/l or g/L 
Biochemistry 
Sodium - HYPONATRAEMIA 120-130 mmol/l <120 mmol/l 
Sodium - 
HYPERNATRAEMIA 
155 – 160 mmol/l >160 mmol/l 
Potassium 2.5 – 3.0 mmol/l <2.5 mmol/l 
Potassium 6.0 – 7.0 mmol/l >7.0 mmol/l 
Hypocalcemia 1.5-1.75 mmol/l <1.5 mmol/l 
Hypercalcemia 3.1-3.4 mmol/l >3.4 mmol/l 
Hypomagnesemia 0.3-0.4 mmol/l <0.3 mmol/l 
Hypermagnesemia 1.23-3.3 mmol/l > 3.3 mmol/l 
Blood glucose 1.7 – 2.2 mmol/l or 30-40 mg/dl 
13.9-27.8 mmol/l or 250-500 mg/dl 
<1.7 mmol/l or < 30 mg/dl 
>27.8 mmol/l or >500 mg/dl 
Creatinine 
 
>3X BASELINE OR 




>5-20-X ULN >20X ULN 
Alanine aminotransferase 
(ALT) 
>5-20-X ULN >20X ULN 
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ULN for Creatinine: 1.36 mg/dL (males), 1.13 mg/dL (females) 345 
ULN for AST/ALT: 40 IU 346 
General conventions and mock-up tables/templates 347 
General conventions 348 
- All patients randomized up to the time-point of the interim analysis database snapshot will be 349 
included in the tables following an intention-to-treat principle. Tables will contain actual 350 
(placebo, tamoxifen) and not masked treatment names. 351 
- Statistical tests will report raw p-values and confidence intervals without any adjustment for 352 
multiplicity. As described in the protocol stopping for harm of Tamoxifen will be considered if a 353 
safety issue emerges which is sufficiently large, in the judgement of the DSMB, to suggest that 354 
continued exposure of patients to Tamoxifen is unethical. Early stopping for efficacy of 355 
Tamoxifen is not foreseen as this is a pilot study. 356 
- As a guidance for stopping early for harm of tamoxifen, the DSMB should consider the following 357 
information: 358 
 A p-value <0.01 in the direction of harm at an interim analysis. 359 
 Clear evidence of harm of tamoxifen in terms of safety or morbidity in the absence 360 
of any evidence of a survival benefit due to tamoxifen. 361 
Below are mock-up tables/templates of all information that is planned to be provided to the DMEC.  362 
 363 







 n Summary statistic n Summary statistic 
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Age (years) XXX  XX (XX, XX) XXX  XX (XX, XX) 
Sex – male XX XX (XX%) XXX XX (XX%) 
Glasgow Coma Score 
 - 15 
-  11 to 14 































n refers to the number of patients included in the summary statistic, the summary statistic is the 365 
number (%) of patients with the characteristic for categorical data and median (IQR) for 366 
continuous data.  367 
Note: Table 1 will be generated for all patients, and for patients according to HIV infection status.  368 
 369 
 370 










CSF per day 






                                                                                  










HIV Infected Patients 
 
























Table 3: Summary of key secondary outcome: survival outcome. 373 
Population No. of deaths Hazard ratio  
(95% CI) 























X.XX (X.XX, X.XX) 










- <5 log10 CFU/ml 











X.XX (X.XX, X.XX) 








* Hazard ratios and p-values are based on stratified Cox proportional hazards models allowing for 374 
separate baseline hazards according to HIV serostatus, except for subgroup analysis of HIV 375 
status, model without stratification will be used. 376 
Figure 1: Kaplan-Meier curves of overall survival by treatment arm. 377 
Standard Kaplan-Meier curves for the two treatment groups with numbers at risk at the bottom will be 378 
displayed. The time axis of the Kaplan-Meier curves will extend to the maximum follow-up 379 
duration of 70 days. 380 
Note: Figure 1 will be generated for all patients only.  381 
Figure 2: Kaplan-Meier curves of overall survival by treatment arm and stratified HIV status.  382 
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n refers to the number of patients included in the analysis of each outcome. Relapse is defined as need 384 
for antifungal treatment intensification or readmission for treatment of cryptococcal disease (as 385 
in the protocol). All analyses were done as outlined in the protocol. 386 
 387 
Note: Table 3 will be generated for all patients and by HIV infection status.  388 
Table 5: Summary of clinical grade 3&4 adverse events. 389 
Characteristic Tamoxifen  
(N=XX) 





 n.pt n.ae n.pt n.ae  
Any adverse event XX (XX%) XX (XX%) XX (XX%) XX (XX%) X.XX 
New Cardiac Event XX (XX%) XX (XX%) XX (XX%) XX (XX%) X.XX 
Neurological event  XX (XX%) XX (XX%) XX (XX%) XX (XX%) X.XX 
New AIDS defining illness XX (XX%) XX (XX%) XX (XX%) XX (XX%) X.XX 
… (other collected AE) … XX (XX%) XX (XX%) XX (XX%) XX (XX%) X.XX 
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n.pt refers to the number of patients with at least one event, n.ae to the total number of adverse event 390 
episodes. Comparison between the two groups based on the number of patients with at least 391 
one adverse event and Fisher’s exact test. 392 
Note: Table 5 will be generated for all patients. AIDS defining illness will only be defined for patients 393 
who are HIV seropositive.  394 
Table 6: Summary of laboratory grade 3&4 adverse events. 395 
Table 7: Summary of serious adverse events. 396 
Table 8: Summary of unexpected serious adverse events. 397 










Stan code of the joint model 408 
data{ 409 
  //for longitudinal data 410 
  int<lower=1> N_long; // no. rows 411 
  int<lower=0,upper=1> y2_censInd[N_long]; // under detection limit index 412 
  int<lower=1> I; // no. patient 413 
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  int<lower=1,upper=I> patid[N_long]; //patid  index for random effect 414 
   415 
  vector [N_long]time_scale; // time_scale censoring data 416 
  real log10fc_obs[N_long];// log10fc observing data 417 
  real <upper=log10(5)>C; 418 
  int<lower=1> p_X; 419 
  int<lower=1> p_X_intercept; 420 
  int<lower=1> p_X_slope; 421 
  vector[p_X]mean_X; 422 
  vector<lower=0>[p_X]sd_X; 423 
  matrix[N_long,p_X] X_long_scale;//treatment on EFA 424 
   425 
  // for survival data 426 
  matrix[I,p_X_intercept] X_intercept_unscale;//treatment on EFA 427 
  matrix[I,p_X_slope] X_slope_unscale;//treatment on EFA; .~trt.group only 428 
  int<lower=0> p_Z; 429 
  matrix<lower=0>[I,p_Z] Z; //treatment on survival 430 
  real<lower=0,upper=71>ttdeath[I]; 431 
  int<lower=0> n_time_interval; 432 
  vector<lower=0,upper=71>[n_time_interval+1]time_spec; 433 
  vector<lower=0,upper=1>[I] death; 434 
  matrix<lower=0>[I,n_time_interval]zeros; 435 





  //for longitudinal data 440 
  vector[p_X] fix_eff_scale;//fixed effects  for intercept 441 
  real<lower=0> sigma; // SD of error measurement 442 
  cholesky_factor_corr[2] L_Omega; // prior correlation 443 
  vector<lower=0,upper=pi()/2>[2] tau_unif; 444 
  //vector<lower=0>[2] tau; // prior scale 445 
  matrix[2,I] z; 446 
  // for survival data 447 
  vector[p_Z] beta;//fixed effects for survival 448 
  real<lower=0>lambda[n_time_interval]; // piecewise hazard rate 449 
  real eta;// trajectory parameter 450 
  real<lower=0> sigma_lambda;  451 
} 452 
 453 
transformed parameters { 454 
  // for longitudinal data 455 
  vector[p_X_slope] b_fix_unscale;//original fixed effects for slope 456 
  vector[p_X_intercept] a_fix_unscale;//original fixed effects  for intercept 457 
  vector[N_long]fit_X_long_scale; 458 
  vector[I] a_unscale;// estimated intercept 459 
  vector[I] b_unscale;// estimated slope 460 
    461 
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  matrix[I,2] U_raw; // patient random effects 462 
  matrix[I,2] U_raw_unscale; // patient random effects 463 
  // for survival data 464 
  vector[I] beta_hat; 465 
  real test; 466 
  vector<lower=0>[2] tau; // prior scale for random effects 467 
  for (k in 1:2) tau[k] = 2.5 * tan(tau_unif[k]); 468 
   469 
  test=sum((fix_eff_scale[2:p_X].*mean_X[2:p_X])./sd_X[2:p_X]); 470 
  a_fix_unscale[1]=fix_eff_scale[1]-sum((fix_eff_scale[2:p_X].*mean_X[2:p_X])./sd_X[2:p_X]); 471 
  a_fix_unscale[2:p_X_intercept]=fix_eff_scale[2:p_X_intercept]./sd_X[2:p_X_intercept]; 472 
  b_fix_unscale=(fix_eff_scale[(p_X_intercept+1):p_X])./sd_X[(p_X_intercept+1):p_X]; 473 
   474 
  U_raw = (diag_pre_multiply(tau,L_Omega) * z)'; 475 
  for(i in 1:I){ 476 
  U_raw_unscale[i,1]= U_raw[i,1]-(U_raw[i,2])*mean_X[(p_X_intercept+1)]/sd_X[(p_X_intercept+1)];   477 
  } 478 
  U_raw_unscale[,2] = U_raw[,2]/sd_X[(p_X_intercept+1)]; 479 
  // compute individual intercept 480 
  fit_X_long_scale=X_long_scale*fix_eff_scale; 481 
  a_unscale=X_intercept_unscale*a_fix_unscale+U_raw_unscale[,1];// contains only random effects. 482 
  // // compute individual  slope 483 
  for( i in 1:I){ 484 
  b_unscale[i]=X_slope_unscale[i,]*b_fix_unscale+U_raw_unscale[i,2]; 485 
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  } 486 
  //for survival data 487 




vector[N_long] mu; 492 
vector[I] H;//cummulative hazard function; 493 
vector[I] LL;//log density function 494 
matrix[I,n_time_interval] integral_ht;// cummulative hazard function 495 
// Likelihood for longitudinal component 496 
// Set all priors for all parameters of longitudinal component 497 
fix_eff_scale~normal(0,10); 498 
to_vector(z) ~ normal(0,1); 499 
tau_unif ~ uniform(0,pi()/2); 500 
L_Omega ~ lkj_corr_cholesky(2); 501 
 502 
for (k in 1:N_long){ 503 
  mu[k]=fit_X_long_scale[k]+U_raw[patid[k],1]+(U_raw[patid[k],2])*time_scale[k]; 504 
  if(y2_censInd[k]==0){ 505 
    log10fc_obs[k] ~ normal(mu[k],sigma); 506 
  }else{ 507 
    target +=normal_lcdf(C|mu[k],sigma); 508 




//Likelihood for survival component 512 
//Compute the cumulative hazard function from 0 to ttdeath. 513 
integral_ht=zeros; 514 
for( i in 1:I){ 515 
integral_ht[i,index_interval[i]] = 516 
lambda[index_interval[i]]*exp(eta*a_unscale[i]+beta_hat[i])*(exp((eta*b_unscale[i])*ttdeath[i])517 
-exp((eta*b_unscale[i])*time_spec[index_interval[i]]))/(eta*b_unscale[i]); 518 
for(j in 1:(index_interval[i]-1)){ 519 
integral_ht[i,j] = lambda[j]*exp(eta*a_unscale[i]+beta_hat[i])*(exp((eta*b_unscale[i])*time_spec[j+1])-520 
exp((eta*b_unscale[i])*time_spec[j]))/(eta*b_unscale[i]); 521 
} 522 
//Integrated hazard for individual i from 0 to survival time t.surv[i] 523 
H[i]=sum(integral_ht[i,]);// cummulative hazard function 524 




target += sum(LL); 529 
 530 
//Set all priors for all parameters of survival component 531 
beta ~ normal(0,10); 532 
if(n_time_interval>2){ 533 
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lambda[1] ~ lognormal(0,5);   534 
}else{ 535 
  lambda[1] ~ normal(0,5);  536 
} 537 
 538 
for(i in 2:n_time_interval){ 539 
  lambda[i]~lognormal(lambda[i-1],sigma_lambda); 540 
} 541 
sigma_lambda~cauchy(0,2.5); 542 
eta ~ normal(0,10); 543 
} 544 
generated quantities { 545 
vector[p_X_slope] b_fix_unscale_true; 546 
  b_fix_unscale_true[1]=b_fix_unscale[1]; 547 
  for(i in 2:p_X_slope){ 548 
    b_fix_unscale_true[i]=b_fix_unscale[1]+b_fix_unscale[i]; 549 
  550 
 
 
Section 2 Data Monitoring Committee charter 551 
Data Monitoring Committee (DMC) Overview 552 
1. Trial Description and Study Design 553 
Trial number: 28CN 554 
Trial design: A randomized trial of Tamoxifen combined with amphotericin B and fluconazole for 555 
cryptococcal meningitis 556 
Trial sponsor: University of Oxford 557 
Number of patients: 50 558 





nvestigators: Dr Jeremy Day, Dr Nguyen Le Nhu Tung, Dr Le Quoc Hung. 564 
2. DMC Terms of Reference 565 
This independent DMC has been convened to assess the progress of a clinical study, the safety data and 566 
provide recommendations to the sponsor. The members of the DMC serve in an individual 567 
capacity and provide their expertise and recommendations. The DMC will review cumulative 568 
study data to evaluate safety, study conduct, and data integrity of the study. This charter will 569 
outline the roles and responsibilities and serve as the standard operating procedure (SOP) for 570 
the DMC 571 
1. To consider the data from interim analyses, information from the investigators and relevant 572 
information from other sources 573 
# Country City Name of site Site number 
1 Viet Nam Ho Chi Minh Hospital for Tropical Diseases 03 
2 Viet Nam Ho Chi Minh Cho Ray Hospital 11 
 
 
2. In the light of 1, and ensuring that ethical considerations are of prime importance, to report 574 
(following each DMC meeting or special meeting if required) to the study sponsor and to 575 
recommend on the continuation of the trial 576 
3. To determine if additional interim analyses of trial data should be undertaken 577 
4. To consider any requests for release of interim trial data and to recommend on the advisability 578 
of this 579 
3. DMC Membership 580 
This charter will be agreed by all DMC members Composition of membership will be: 581 
Chairperson: Professor Tim Peto (Professor of Medicine, Consultant Physician in Infectious Diseases, 582 
General Physician) 583 
Independent members: Dr Matt Scarborough (Consultant, Infectious Diseases and General Medicine, 584 
OUH NHS trust), Dr Nguyen Duc Bang (Infectious Disease physician, Pham Ngoc Thach Hospital, 585 
Ho Chi Minh City, Viet Nam) 586 
Acronyms 587 
CTU – Clinical Trials Unit (of OUCRU-VN) 588 
DMC – Data Monitoring Committee 589 
OUCRU-VN – Oxford University Clinical Research Unit – Viet Nam  590 
PI – Principal Investigator 591 
TMG – Trial Management Group 592 
Introduction 593 
The purpose of this charter is to define the roles and responsibilities of the Data Monitoring Committee 594 
(DMC), delineate qualifications of the membership, describe the purpose and timing of 595 
meetings, provide the procedures for ensuring confidentiality and proper communication, and 596 
outline the content of the reports. 597 
 
 
The DMC will function in accordance with the ICH guidelines for Good Clinical Practice and the approved 598 
trial protocol. 599 
The DMC administration will be coordinated by the OUCRU-VN Clinical Trials Unit. All significant 600 
communications, meetings and reports will be made in writing, communicated to all relevant 601 
parties and maintained with the Trial Master File. 602 
Definitions 603 
The following definitions apply to this protocol: 604 
(S)AE 605 
TABLE DEFINITION 
Adverse Event (AE) Any untoward medical occurrence in a participant or clinical trial 
subject to whom an investigational medicinal product has 
been administered including occurrences that are not 
necessarily caused by or related to that product. 
Grade 3 or 4 Adverse Event: Any untoward medical occurrence of severity defined as grade 3 
or 4 by the Common Terminology Criteria for Adverse 
Events from National Cancer Institute (CTCAE) 
http://ctep.cancer.gov/protocolDevelopment/electronic_
applications/ctc.htm 
Adverse Reaction (AR) Any untoward and unintended response to an investigational 
medicinal product related to any dose administered. 
Unexpected Adverse Reaction (UAR) An adverse reaction, the nature or severity of which is not 
consistent with the information about the investigational 
 medicinal product in question set out in the Summary of Product 
 
 
Characteristics (SPC) for that product. 
Serious Adverse Event (SAE) or Serious 
Adverse Reaction (SAR) or 
Suspected Unexpected Serious 
Adverse Reaction (SUSAR) 
Respectively any adverse event, adverse reaction or unexpected 
adverse reaction that: 
Results in death 
Is life-threatening* 
Requires hospitalization or prolongation of existing 
hospitalization** 
Results in persistent or significant disability or incapacity 
Consists of a congenital anomaly or birth defect 
Is another important medical condition*** 
*The term life-threatening in the definition of a serious event refers to an event in which the participant 606 
is at risk of death at the time of the event; it does not refer to an event that hypothetically might 607 
cause death if it were more severe, for example, a silent myocardial infarction. 608 
**Hospitalization is defined as an in-participant admission, regardless of length of stay, even if the 609 
hospitalization is a precautionary measure for continued observation. Hospitalizations for a pre-610 
existing condition (including elective procedures that have not worsened) do not constitute an 611 
SAE. 612 
*** Medical judgement should be exercised in deciding whether an AE or AR is serious in other 613 
situations. The following should also be considered serious: important AEs or ARs that are not 614 
immediately life-threatening or do not result in death or hospitalization but may jeopardize the 615 
subject or may require intervention to prevent one of the other outcomes listed in the definition 616 
above; for example, a secondary malignancy, an allergic bronchospasm requiring intensive 617 
emergency treatment, seizures or blood dyscrasias that do not result in hospitalization or 618 
development of drug dependency. 619 
 
 
Ethical Committee of Reference: the lead ethical committee to which all safety reporting and DSMB 620 
reports are issued. In the case of this trial, the ethical committee of reference is the Oxford 621 
Tropical Research Ethics Committee. 622 
Roles and Responsibilities 623 
DMC Roles and Responsibilities 624 
1. This DMC will 625 
• Receive, review and feedback when necessary on USAEs reported in detail within 2 weeks of 626 
occurrence and followed until resolution 627 
• Meet periodically (see DMC Meetings) to review summary tables of serious adverse events 628 
(SAEs), grade 3 & 4 AEs. The DMC may request additional data as required including aggregate 629 
and individual subject data related to safety, data integrity and overall conduct of the trial. 630 
• Provide recommendations to continue, modify or terminate the trial depending upon these 631 
analyses. 632 
• Communicate other recommendations or concerns as appropriate including requests for 633 
additional reviews based on regular reporting and USAE reporting. 634 
• Comply with and operate according to the procedures described in this charter. 635 
• Maintain documentation and records of all activities as described below (see DMC Chairman, 636 
DMC Meetings, DMC Reports). 637 
• DMC members will have the ability to review unmasked clinical data (this will only be discussed 638 
during closed sessions). 639 
• Consider factors external to the study when relevant information becomes available, such as 640 
scientific or therapeutic developments that may have an impact on the safety of the participants 641 
or the ethics of the study. 642 
• What about review the conduct of the study including protocol violations? 643 
 
 
2. DMC Chairman will 644 
• Be responsible to archive the interim analysis reports and documentation of rationale for 645 
decisions made by the Committee during closed sessions. These will be provided to the Principal 646 
Investigator upon completion of the trial. 647 
3. DSMB Statistician will 648 
• Generate the analysis tables and distribute the interim report amongst the DSMB members as 649 
described below (see section “Creation of interim analysis reports” below). 650 
Principal Investigator Roles and Responsibilities  651 
The PI will directly or through delegation: 652 
• Assure the proper conduct of the study including collection of accurate and timely data. 653 
• Compile and report USAEs as described below. 654 
• Promptly report potential safety concern(s) to the DMC. 655 
• Communicate with regulatory authorities, ethical committees and investigators, in a manner 656 
that maintains patient safety and integrity of the data. 657 
DMC Participation 658 
Membership will be selected by the Principal Investigator and approved by the trial Sponsor. If a DMC 659 
member is unable to continue participation on the board, the reason will be documented and a 660 
replacement will be selected by the Principal Investigator with the agreement of the other DMC 661 
members and endorsement of the Sponsor. 662 
DMC members will declare any existing or potential conflicts of interest to the Principal Investigator who 663 
will report to the Sponsor. Conflicts of interest will be reduced to the greatest extent that is 664 
consistent with assembling an independent and highly competent DMC. Any questions or 665 
concerns that arise regarding conflicts of interest will be addressed by the DMC Chair and the 666 
Sponsor if necessary. In the case of the Chair having a conflict, by the Sponsor. 667 
 
 
A conflict of interest exists or potentially exists when a member has a personal, professional or financial 668 
interest which could unduly influence the member’s position with respect to the trial or trial 669 
related issues. A conflict of interest should also be addressed if an interest could result in the 670 
member’s objectivity being questioned by others. 671 
DMC Meetings 672 
1. Projected Schedule of Meetings 673 
Correspondence with the DMC will be initiated by the OUCRU Clinical Trials Unit prior to any subject 674 
enrollment in the trial in order for the members to review the charter, to discuss the protocol, 675 
agree to the safety reporting procedures, to establish a meeting schedule and to review the 676 
study modification and/or termination guidelines. Subsequent interim review meetings will be 677 
held to review and discuss interim study data according to the schedule below. Additional 678 
meetings may be scheduled at the request of the DMC Chairman or the Sponsor. If scheduled 679 
meetings are more than 12 months apart, the DMC Chairman may consider an additional 680 
interim review. 681 
Timeline Data Review by Type of Data 
Before study initiation Entire DMC Study protocol, safety concerns, DMC Charter and 
associated procedures/reports 




Entire DMC Enrolment summary 
Tables of grade 3 & 4 AEs and SAEs, SARs and SUSARs. 
Any other requested data 
 682 
2. Meeting Format 683 
 
 
DMC meetings will generally be conducted by teleconference and coordinated by the OUCRU-VN CTU. A 684 
quorum, defined as a minimum of 2 members (including the Chairman) will be required to hold 685 
a DMC meeting. Any member of the DMC may be absent during the meeting provided data 686 
tables are circulated in advance and the member has opportunity to forward any concerns to 687 
the Chairman before the meeting. Decisions of the DMC should be made by unanimous 688 
consensus. However, if this is not possible, majority vote will decide. When appropriate, DMC 689 
review sessions may be held by email exchange in lieu of a meeting. 690 
3. Open and Closed Sessions 691 
Sessions may be open (attended by representatives of the sponsor and study team) or closed (attended 692 
only by DMC members) at the direction of the DMC. A report based on each DMC meeting will 693 
be organized by the Chairman and submitted to the Sponsor. This report will include a 694 
recommendation to: 695 
- Continue the trial without modification 696 
- Continue the trial with modification 697 
- Stop the trial due to safety concerns 698 
- Stop the trial for another reason 699 
Reports will be circulated to all DMC members for their approval before being issued. 700 
4. Creation & conduct of interim analysis reports 701 
The study statistician will generate the code (in the statistical software R) to generate all tables outlined 702 
in the Interim Analysis Plan. The intention is to analyze safety outcomes only to prevent 703 
stopping the study when important secondary outcomes including antibiotic use may not yet be 704 
clear. 705 
Prior to each interim analysis, raw data will be transferred from the study statistician to the DMC 706 
statistician together with R code to generate all summary tables. Based on this information, the 707 
 
 
DMC statistician generates the tables and distribute the interim report amongst the DMC 708 
members. 709 
Interim analysis plan 710 
All planned analyses will be described in detail in a full Statistical Analysis Plan. This section summarizes 711 
the main issues. 712 
1. Analysis populations 713 
The primary analysis population for all analyses is the full analysis population containing all randomized 714 
patients. Patients will be analyzed according to their randomized arm (intention-to-treat). In 715 
addition, the primary end point will be analyzed in the per-protocol population, which will 716 
exclude the following patients: patients with a final diagnosis other than TBM, major protocol 717 
violations and those receiving less than 1 week of administration of the randomized study drug 718 
for reasons other than death. 719 
Of note, this trial includes a nested trial which randomizes participants who develop drug-induced liver 720 
injury to one of three management strategies as a sub-study (see Section 12.1 in the protocol 721 
for an outline). For the primary analyses of the main trial this second randomization will be 722 
ignored and the estimated dexamethasone treatment effect can thus be interpreted as an 723 
average effect across these three management strategies. We believe that this is justified 724 
because only approximately 100 (19%) subjects are expected to be enrolled in the nested trial 725 
with roughly similar numbers from both arms, because the efficacy of the different 726 
management strategies is unlikely to depend on whether the patient receive dexamethasone or 727 
not as it tests a very different intervention, and because the anticipated effect of the 728 
management strategy on survival is relatively small. However, in a supplementary analysis, we 729 
will also compare the primary endpoint between the treatment policies “dexamethasone 730 
treatment plus standard of care management of drug-related liver injury” vs. “placebo 731 
 
 
treatment plus standard of care management of drug-related liver injury” using an inverse 732 
probability weighting based analytical framework. 733 
2. Analysis of primary endpoint 734 
The primary endpoint of this trial is overall survival, i.e. time from randomization to death, during 12 735 
months of follow-up. Overall survival will be analyzed with a Cox proportional hazards 736 
regression model with treatment as the only covariate and stratification by TBM MRC severity 737 
grade at enrolment (I, II, or III) and country (Vietnam or Indonesia). The primary effect measure 738 
is the resulting hazard ratio comparing dexamethasone vs. placebo with a corresponding two-739 
sided 95% confidence interval and p-value. The significance level of the associated two-sided 740 
test will be set to 5%. Kaplan-Meier plots and explicit survival estimates at 3, 6, 9, and 12 741 
months of follow-up will also be calculated for the full populations and in the subgroups defined 742 
by TBM disease severity and country separately. 743 
The proportional hazards assumption will be formally tested based on scaled Schoenfeld residuals and 744 
visually assessed by a plot of the scaled Schoenfeld residuals versus transformed time. In case of 745 
a significant test, a formal comparison of the absolute risk of death at 12 months between the 746 
two groups will also be performed (using a Wald-type test based on Kaplan-Meier estimates at 747 
12 months and associated standard errors using Greenwood’s formula). 748 
The homogeneity of the treatment effect on overall survival across subgroups will be assessed by 749 
subgroup analyses and formal tests of interaction between treatment and the following 750 
grouping variables: TBM MRC severity grade at enrolment (I, II, or III), country (Vietnam or 751 
Indonesia), drug resistance pattern (MDR-TB or rifampicin mono-resistance, isoniazid resistant 752 
non-MDR, no or other resistance), ART status at enrolment (ART naïve, ≤3 months of ART, >3 753 
months of ART), and CD4 cell count at enrolment (≤100 vs >100 cells/mm3). 754 
 
 
To obtain an adjusted treatment effect estimate and to assess the effect of other covariates on survival, 755 
the primary endpoint will also be modeled using a multivariable Cox proportional hazards 756 
regression model including the following covariates (in addition to the treatment group): TBM 757 
MRC severity grade at enrolment, country, drug resistance pattern, ART status and CD4 cell 758 
count at enrolment. Multiple imputation will be used to handle missing covariates. 759 
3. Analysis of secondary efficacy endpoints 760 
Neurological disability (as assessed by the ordinal modified Rankin scale) at 12 months will be compared 761 
between the two arms with a proportional odds logistic regression model with the treatment 762 
assignment as the main covariate and adjustment for TBM MRC severity grade, and country. The 763 
result will be summarized as a cumulative odds ratio with corresponding 95% confidence 764 
interval and p‐value. Patients with a missing 12-month disability assessment will be excluded 765 
from the main analysis but an alternative analysis based on multiple imputation (including 766 
disability assessments at earlier time points in the imputation model) will also be performed. 767 
Secondary time-to-event endpoints (time to neurological event or death, time to new AIDS event or 768 
death) will be analyzed in the same way as the primary endpoint. The number of IRIS and HIV-769 
associated malignancy events in each group will be summarized and the event rate calculated in 770 
each arm. Comparisons of the rates between the treatment arms will be based on a cause-771 
specific proportional hazards model of the time to the first IRIS event (or HIV-associated 772 
malignancy, respectively) or death with treatment as the only covariate. 773 
4. Analysis of adverse event 774 
The number of patients with any adverse events and specific events, respectively, will be summarized 775 
and informally compared between the two treatment arms based on Fisher’s exact test. The 776 
total number of adverse event episodes per patient will also be summarized and informally 777 
compared based on a quasi- Poisson regression model with treatment as the only covariate. 778 
 
 
The following subgroups of adverse events will also be separately summarized: grade 3&4 adverse 779 
events; serious adverse events; serious adverse events possibly, probably, or definitely related 780 
to the study drug; adverse events leading to TB treatment or ARV interruptions. Grade 3&4 781 
laboratory abnormalities will be summarized in the same way as clinical adverse events. 782 
5. Baseline descriptive analyses 783 
Baseline characteristics will be summarized as median (lower and upper quartiles) for continuous data 784 
and frequency (percentage) for categorical data. The amount of missing data for each baseline 785 
characteristic will also be displayed. 786 
Study Review Criteria, Stopping Rules and Guidelines 787 
1. Safety Analyses 788 
The primary safety endpoint is survival. In addition to the primary safety endpoint, the DMC will 789 
consider grade 3 & 4 adverse events, serious adverse events and unexpected or events 790 
concerning to the Investigators at the time points defined above. 791 
2. Consideration of External Data 792 
The DMC will also consider data from other studies or external sources during its deliberations, if 793 
available, as these results may have an impact on the status of the patients and design of the 794 
current study. 795 
DMC Reports 796 
1. Monitoring for Safety 797 
The primary charge of the DMC is to monitor patient safety during the study. Formal DMC safety reviews 798 
will occur as specified above (see DMC Meetings). 799 
Safety reporting to regulatory and ethical committees will be in accordance with the requirements of 800 
each committee and the study protocol. 801 
2. Content of DMC Reports at Formal Interim Analyses 802 
 
 
The detailed content of the interim analysis report will be outlined in a separate document, the Interim 803 
Analysis Plan. 804 
3. Monitoring for Study Conduct 805 
The DMC will be updated at each scheduled meeting on study enrolment and major operational issues. 806 
4. DMC Communication of Findings and Recommendations 807 
Following each meeting and within 2 weeks of the meeting the chairman will send findings and 808 
recommendations of the DMC in writing to the Sponsor. The report should include the date of 809 
the meeting, participants, data reviewed by the Committee and a recommendation to continue 810 
the trial with/without modification or to stop the trial on a specified basis. The report may 811 
include minutes of relevant non- confidential discussion points and any requests for clarification 812 
of further information. 813 
These findings and recommendations can result from both the open and closed sessions of the DMC. If 814 
these findings include serious and potentially consequential recommendations that require 815 
immediate action, the chairman will promptly notify the Principal Investigator and sponsor. 816 
5. Response to DMC Findings and Recommendations 817 
The Sponsor will review and respond to the DMC recommendations. If the DMC recommends 818 
continuation of the study without modification, no formal response will be required. If the 819 
recommendations request action, such as a recommendation for termination of the study or 820 
modification of the protocol, the Sponsor or Principal Investigator will provide a response 821 
stating whether the recommendations will be followed and the plan for addressing the issues. 822 
Upon receipt, the DMC will consider the response and will attempt to resolve relevant issues, resulting 823 
in a final decision. 824 
The Principal Investigator will disseminate all DMC reports to the relevant ethical committees according 825 
to the reporting requirements of that committee. 826 
 
 
DMC Study Closeout 827 
This study may be terminated based on safety issues or DMC monitoring guidelines. A final study report 828 
will be issued to the DMC who may recommend continuing action items to the Sponsor based 829 
upon the report. 830 
Confidentiality 831 
All data provided to the DMC and all deliberations of the DMC will be privileged and confidential. The 832 
DMC will agree to use this information to accomplish the responsibilities of the DMC and will 833 
not use it for other purposes without written consent from the Sponsor. No communication of 834 
the deliberations or recommendations of the DMC, either written or oral, will occur except as 835 
required for the DMC to fulfill its responsibilities. Individual DMC members must not have direct 836 
communication regarding the study outside the DMC (including, but not limited to the 837 
investigators, IRB/EC, regulatory agencies, or sponsor) except as authorized by the DMC. 838 
Amendments to the DMC Charter 839 
This DMC charter can be amended as needed during the course of the study. All amendments will be 840 
documented with sequential revision dates, and will be recorded in the report from the DMC 841 
meetings. Each revision will be reviewed and agreed upon by the DMC, the Principal Investigator 842 
and the Sponsor. All versions of the charter will be archived in the Trial Master File. 843 
Archiving of DMC Activities and Related Documents 844 
All DMC documentation and records will be retained in the Trial Master File in accordance with local and 845 
international regulatory requirements. 846 
Agreement of DSMB Members 847 
Signatures below confirm the agreement of all DSMB members to the contents of this charter and the 848 
confidentiality statement above. 849 




Name: Dr Matt Scarborough   Date:    Signature: 852 
 853 
Name: Dr Nguyen Duc Bang   Date:    Signature: 854 
 855 
Agreement of Sponsor 856 
Signatures below confirm the agreement of the Sponsor with the contents of this charter. 857 
Name: Evelyne Kestelyn        Date:          Signature: 858 
 
 




Difference of QTC between study arms 
before drug using (95% CI) 
Difference of QTC between study arms 2 
hours after drug using (95% CI) 
0 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 
1 3.73 (-0.29, 7.74) 7.44 (3.45, 11.44) 
2 7.63 (0.09, 15.18) 14.51 (6.99, 22.02) 
3 11.91 (1.75, 22.06) 20.8 (10.69, 30.92) 
4 16.73 (5.2, 28.25) 25.96 (14.47, 37.45) 
5 22.13 (10.28, 33.97) 29.68 (17.85, 41.5) 
6 27.55 (15.32, 39.78) 32.05 (19.82, 44.27) 
7 32.29 (18.96, 45.62) 33.24 (19.92, 46.57) 
8 35.63 (20.85, 50.42) 33.44 (18.67, 48.21) 
9 37.07 (21.09, 53.04) 32.82 (16.86, 48.77) 
10 36.82 (19.81, 53.83) 31.54 (14.55, 48.53) 
11 35.32 (16.92, 53.72) 29.77 (11.39, 48.15) 
12 32.97 (12.41, 53.54) 27.67 (7.13, 48.21) 










Figure The bold lines and the shaded bands represent the estimated mean difference with 95% 869 
Confidence Interval of QTc between two study arms.  The output of the fitted linear mixed effect 870 
model computes the differences in QTc between study arms by study day, separately for pre-871 





Section 4 Adverse events by type and subtype 
Adverse events (AEs) 
Tamoxifen 
(N=24) 




Number of patients with adverse events of any grade (%) 
All AEs combined 24 (100%) 26 (100%) 1 
IMMUNE RECONSTITUTION 
INFLAMMATORY SYNDROME 
0 (0%) 1 (3.85%) 1 
NEW AIDS DEFINING ILLNESS 7 (29.17%) 10 (38.46%) 0.693 
Meningitis tuberculosis 1 (4.17%) 1 (3.85%) 1 
Other AIDS events 1 (4.17%) 3 (11.54%) 0.661 
Other extrapulmonary tuberculosis 1 (4.17%) 0 (0%) 0.48 
Pneumocystis jiroveci pneumonia 3 (12.5%) 6 (23.08%) 0.546 
Cerebral toxoplasmosis 2 (8.33%) 0 (0%) 0.225 
Pulmonary tuberculosis 2 (8.33%) 1 (3.85%) 0.943 
NEW CARDIAC ADVERSE EVENT 23 (95.83%) 24 (92.31%) 1 
QRS axis abnormal (New axis deviation)  3 (12.5%) 1 (3.85%) 0.545 
Supraventricular tachycardia 1 (4.17%) 0 (0%) 0.48 
Ventricular extrasystoles  8 (33.33%) 0 (0%) 0.005 
Bundle branch block right 0 (0%) 1 (3.85%) 1 
Electrocardiogram QT prolonged 18 (75%) 8 (30.77%) 0.004 
Atrioventricular block first degree 2 (8.33%) 2 (7.69%) 1 
Myocardial infarction 0 (0%) 1 (3.85%) 1 
Sinus tachycardia 13 (54.17%) 15 (57.69%) 1 
Cardiac arrest  1 (4.17%) 0 (0%) 0.48 
 
 
Other cardiac adverse event 18 (75%) 13 (50%) 0.127 
Sinus bradycardia 3 (12.5%) 3 (11.54%) 1 
NEW NEUROLOGICAL EVENT 11 (45.83%) 12 (46.15%) 1 
Brain herniation (coning) 0 (0%) 1 (3.85%) 1 
Cranial nerve paralysis 1 (4.17%) 1 (3.85%) 1 
Depressed level of consciousness (fall in GCS 
>=2 points for >=48 hours) 
7 (29.17%) 7 (26.92%) 1 
Headache 1 (4.17%) 0 (0%) 0.48 
Hemiplegia/paresis 1 (4.17%) 0 (0%) 0.48 
Seizure (fit) 3 (12.5%) 5 (19.23%) 0.793 
Other neurological event 2 (8.33%) 5 (19.23%) 0.483 
OTHER ADVERSE EVENT 24 (100%) 26 (100%) 1 
Hypersensitivity (Allergic reaction)  3 (12.5%) 2 (7.69%) 0.925 
Anemia 18 (75%) 18 (69.23%) 0.89 
Diarrhea 3 (12.5%) 2 (7.69%) 0.925 
Hypertension 0 (0%) 2 (7.69%) 0.491 
Hypotension 2 (8.33%) 3 (11.54%) 1 
Jaundice 2 (8.33%) 0 (0%) 0.225 
Hypokalemia 17 (70.83%) 17 (65.38%) 0.913 
Acute Kidney Injury 0 (0%) 3 (11.54%) 0.263 
Pleural effusion 0 (0%) 1 (3.85%) 1 
Pneumonitis 5 (20.83%) 9 (34.62%) 0.442 
Upper gastrointestinal hemorrhage 0 (0%) 1 (3.85%) 1 
Vomit 5 (20.83%) 3 (11.54%) 0.61 
Other adverse event 20 (83.33%) 22 (84.62%) 1 
 
 
  875 
Section 5 Results of drug interactions from two‐dimensional chequerboard testing of tamoxifen in 876 
combination with either amphotericin, fluconazole. 877 
Antifungal combination 
Proportion (%) of isolates where particular drug interactions was 
observed£ 
Synergy 
FICI ≤ 0.5 
No interaction 
0.5 < FICI ≤ 4 
Antagonism 
FICI > 4 
C. neoformans    
Tamoxifen + amphotericin 11 (5/47) 89 (42/47) 0 (0/47) 
Tamoxifen + fluconazole 4 (2/47) 96 (45/47) 0 (0/47) 
C. gattii    
Tamoxifen + amphotericin 33 (1/3) 67 (2/3) 0 (0/3) 
Tamoxifen + fluconazole 0 (0/3) 100 (3/3) 0 (0/3) 
£ Numbers in brackets: Numerators are the numbers of strains where interaction was observed; denominators 
are the numbers of isolates tested. 
 878 
 879 
ⱡp-values were not corrected for multiple testing.  
